A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

Abstract

Many sarcomas and leukemias carry nonrandom chromosomal translocations encoding tumor-specific mutant fusion transcription factors that are essential to their molecular pathogenesis. Ewing's sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1. EWS-FLI1 is a disordered protein that precludes standard structure-based small-molecule inhibitor design. EWS-FLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. We therefore used surface plasmon resonance screening to identify compounds that bind EWS-FLI1 and might block its interaction with RHA. YK-4-279, a derivative of the lead compound from the screen, blocks RHA binding to EWS-FLI1, induces apoptosis in ESFT cells and reduces the growth of ESFT orthotopic xenografts. These findings provide proof of principle that inhibiting the interaction of mutant cancer-specific transcription factors with the normal cellular binding partners required for their oncogenic activity provides a promising strategy for the development of uniquely effective, tumor-specific anticancer agents.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: RHA is necessary for optimal transformation by EWS-FLI1.
Figure 2: E9R peptide prevents EWS-FLI1 binding to RHA with specific detrimental effects upon ESFT growth and transformation.
Figure 3: Small molecule binds EWS-FLI1 and displaces E9R from EWS-FLI1.
Figure 4: YK-4-279 reduces EWS-FLI1 functional activity.
Figure 5: YK-4-279 is a potent and specific inhibitor of ESFTs.
Figure 6: YK-4-279 inhibits the growth of ESFT xenograft tumors.

References

  1. 1

    Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245 (2007).

  2. 2

    French, C.A. et al. Midline carcinoma of children and young adults with NUT rearrangement. J. Clin. Oncol. 22, 4135–4139 (2004).

  3. 3

    Helman, L.J. & Meltzer, P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685–694 (2003).

  4. 4

    Poppe, B. et al. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 103, 229–235 (2004).

  5. 5

    Carroll, M. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947–4952 (1997).

  6. 6

    Grier, H.E. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694–701 (2003).

  7. 7

    Delattre, O. et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294–299 (1994).

  8. 8

    Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W., Davis, M.E. & Triche, T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984–8992 (2005).

  9. 9

    Kovar, H., Ban, J. & Pospisilova, S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. 13, 275–281 (2003).

  10. 10

    Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H. & Iwamoto, Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239–247 (1997).

  11. 11

    Petermann, R. et al. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 17, 603–610 (1998).

  12. 12

    Nakatani, F. et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J. Biol. Chem. 278, 15105–15115 (2003).

  13. 13

    Toretsky, J.A. et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 66, 5574–5581 (2006).

  14. 14

    Lee, C.G. et al. RNA helicase A is essential for normal gastrulation. Proc. Natl. Acad. Sci. USA 95, 13709–13713 (1998).

  15. 15

    Hartman, T.R. et al. RNA helicase A is necessary for translation of selected messenger RNAs. Nat. Struct. Mol. Biol. 13, 509–516 (2006).

  16. 16

    Tetsuka, T. et al. RNA helicase A interacts with nuclear factor κB p65 and functions as a transcriptional coactivator. Eur. J. Biochem. 271, 3741–3751 (2004).

  17. 17

    Välineva, T., Yang, J. & Silvennoinen, O. Characterization of RNA helicase A as component of STAT6-dependent enhanceosome. Nucleic Acids Res. 34, 3938–3946 (2006).

  18. 18

    Myöhänen, S. & Baylin, S.B. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J. Biol. Chem. 276, 1634–1642 (2001).

  19. 19

    Zhong, X. & Safa, A.R. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells. J. Biol. Chem. 279, 17134–17141 (2004).

  20. 20

    Nakajima, T. et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90, 1107–1112 (1997).

  21. 21

    Anderson, S.F., Schlegel, B.P., Nakajima, T., Wolpin, E.S. & Parvin, J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19, 254–256 (1998).

  22. 22

    Robb, G.B. & Rana, T.M. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol. Cell 26, 523–537 (2007).

  23. 23

    Bhalla, J., Storchan, G.B., MacCarthy, C.M., Uversky, V.N. & Tcherkasskaya, O. Local flexibility in molecular function paradigm. Mol. Cell. Proteomics 5, 1212–1223 (2006).

  24. 24

    Xie, H. et al. Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J. Proteome Res. 6, 1882–1898 (2007).

  25. 25

    Ng, K.P. et al. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc. Natl. Acad. Sci. USA 104, 479–484 (2007).

  26. 26

    Üren, A., Tcherkasskaya, O. & Toretsky, J.A. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 43, 13579–13589 (2004).

  27. 27

    Terrone, D., Sang, S.L., Roudaia, L. & Silvius, J.R. Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 42, 13787–13799 (2003).

  28. 28

    Voss, S.D., DeGrand, A.M., Romeo, G.R., Cantley, L.C. & Frangioni, J.V. An integrated vector system for cellular studies of phage display-derived peptides. Anal. Biochem. 308, 364–372 (2002).

  29. 29

    Leeson, P.D. & Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881–890 (2007).

  30. 30

    Gangwal, K. et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc. Natl. Acad. Sci. USA 105, 10149–10154 (2008).

  31. 31

    Sanchez, G. et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc. Natl. Acad. Sci. USA 105, 6004–6009 (2008).

  32. 32

    Li, F. et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580–584 (1998).

  33. 33

    Knoop, L.L. & Baker, S.J. EWS/FLI alters 5′-splice site selection. J. Biol. Chem. 276, 22317–22322 (2001).

  34. 34

    Tirode, F. et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11, 421–429 (2007).

  35. 35

    Delattre, O. et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162–165 (1992).

  36. 36

    Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457–468 (2005).

  37. 37

    Palermo, C.M., Bennett, C.A., Winters, A.C. & Hemenway, C.S. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4–11 leukemia cells. Leuk. Res. 32, 633–642 (2008).

  38. 38

    Cheng, Y. et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24, 435–442 (2006).

  39. 39

    Uren, A. et al. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 65, 6199–6206 (2005).

  40. 40

    Frangioni, J.V. & Neel, B.G. Use of a general purpose mammalian expression vector for studying intracellular protein targeting: identification of critical residues in the nuclear lamin A/C nuclear localization signal. J. Cell Sci. 105, 481–488 (1993).

Download references

Acknowledgements

This work was generously supported by the Children's Cancer Foundation of Baltimore (J.T. and A.Ü.), Go4theGoal Foundation (J.T.), Dani's Foundation of Denver (J.T.), the Liddy Shriver Sarcoma Initiative (J.T.), the Amschwand Sarcoma Cancer Foundation (J.T.), the Burroughs-Wellcome Clinical Scientist Award in Translational Research (J.T.), US National Institutes of Health grants R01CA138212 (J.T.) and R01CA133662 (J.T.), and the Georgetown University Medical Center Drug Discovery Program. US National Institutes of Health support is through the Cancer Center Support Grant P30 CA051008 for use of Flow Cytometry and Cell Sorting, Biacore Molecular Interaction, Tissue Culture and microscopy core facilities and grant P01 CA47179 (M.M.). We would like to thank S. Metallo for training in fluorescence polarization. Also, T. Cripe and L. Whitesell provided critical review of our manuscript. We also thank S. Lessnick from Hunstamn Cancer Institute, for providing NROB1 reporter plasmid, J.V. Frangioni from Beth Israel Deaconess Medical Center for providing pG, pGN and pGC vectors, O. Delattre from INSERM France for providing the A673 shEWS-FLI1 cell line, and R. Schlegel, Lombardi Comprehensive Cancer Center, for providing HFK and HEC cell lines. We thank the Developmental Therapeutics Program of the US National Cancer Institute for providing the Diversity set of compounds for screening. This article is dedicated to our patients who have fought but succumbed to ESFT.

Author information

H.V.E., J.S.B.-R., M.M., L.Y., O.D.A., S.S., T.-h.C., A.Ü. and J.A.T. designed and carried out experiments. Y.K., S.D. and M.L.B. designed and synthesized chemical compounds. H.V.E. and J.A.T. wrote the manuscript. All authors reviewed, critiqued and offered comments to the text.

Correspondence to Jeffrey A Toretsky.

Ethics declarations

Competing interests

J.A.T., M.L.B., A.Ü. and Y.K. are inventors on a patent application to the US Patent Office that has been filed by Georgetown University related to the small molecule technology described in this paper.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–5, Supplementary Table 1 and Supplementary Methods (PDF 877 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Erkizan, H., Kong, Y., Merchant, M. et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 15, 750–756 (2009). https://doi.org/10.1038/nm.1983

Download citation

Further reading